Thalidomide	thalidomide	S_chemical	O
has	has	O	O
limited	limited	O	O
single-agent	single-agent	O	O
activity	activity	O	O
in	in	O	O
relapsed	relapsed	O	O
or	or	O	O
refractory	refractory	O	O
indolent	indolent	O	O
non-Hodgkin	non-hodgkin	O	O
lymphomas	lymphomas	O	O
:	:	O	O
a	a	O	O
phase	phase	O	O
II	ii	O	O
trial	trial	O	O
of	of	O	O
the	the	O	O
Cancer	cancer	O	S_disease
and	and	O	O
Leukemia	leukemia	O	O
Group	group	O	O
B.Thalidomide	b.thalidomide	O	O
is	is	O	O
an	an	O	O
immunomodulatory	immunomodulatory	O	O
agent	agent	O	O
with	with	O	O
demonstrated	demonstrated	O	O
activity	activity	O	O
in	in	O	O
multiple	multiple	O	B_disease
myeloma	myeloma	O	I_disease
,	,	O	O
mantle	mantle	O	B_disease
cell	cell	O	I_disease
lymphoma	lymphoma	O	I_disease
and	and	O	O
lymphoplasmacytic	lymphoplasmacytic	O	O
lymphoma	lymphoma	O	O
.	.	O	O

Its	its	O	O
activity	activity	O	O
is	is	O	O
believed	believed	O	O
to	to	O	O
be	be	O	O
due	due	O	O
modulation	modulation	O	O
of	of	O	O
the	the	O	O
tumour	tumour	O	O
milieu	milieu	O	O
,	,	O	O
including	including	O	O
downregulation	downregulation	O	O
of	of	O	O
angiogenesis	angiogenesis	O	O
and	and	O	O
inflammatory	inflammatory	O	O
cytokines	cytokines	O	O
.	.	O	O

Between	between	O	O
July	july	O	O
2001	2001	O	O
and	and	O	O
April	april	O	O
2004	2004	O	O
,	,	O	O
24	24	O	O
patients	patients	O	O
with	with	O	O
relapsed/refractory	relapsed/refractory	O	O
indolent	indolent	O	O
lymphomas	lymphomas	O	O
received	received	O	O
thalidomide	thalidomide	S_chemical	O
200	200	O	O
mg	mg	O	O
daily	daily	O	O
with	with	O	O
escalation	escalation	O	O
by	by	O	O
100	100	O	O
mg	mg	O	O
daily	daily	O	O
every	every	O	O
1	1	O	O
-	-	O	O
2	2	O	O
weeks	weeks	O	O
as	as	O	O
tolerated	tolerated	O	O
,	,	O	O
up	up	O	O
to	to	O	O
a	a	O	O
maximum	maximum	O	O
of	of	O	O
800	800	O	O
mg	mg	O	O
daily	daily	O	O
.	.	O	O

Patients	patients	O	O
had	had	O	O
received	received	O	O
a	a	O	O
median	median	O	O
of	of	O	O
2	2	O	O
(	(	O	O
range	range	O	O
,	,	O	O
1	1	O	O
-	-	O	O
4	4	O	O
)	)	O	O
prior	prior	O	O
regimens	regimens	O	O
.	.	O	O

Of	of	O	O
24	24	O	O
evaluable	evaluable	O	O
patients	patients	O	O
,	,	O	O
two	two	O	O
achieved	achieved	O	O
a	a	O	O
complete	complete	O	O
remission	remission	O	O
and	and	O	O
one	one	O	O
achieved	achieved	O	O
a	a	O	O
partial	partial	O	O
remission	remission	O	O
for	for	O	O
an	an	O	O
overall	overall	O	O
response	response	O	O
rate	rate	O	O
of	of	O	O
12.5	12.5	O	O
%	%	O	O
(	(	O	O
95	95	O	O
%	%	O	O
confidence	confidence	O	O
interval	interval	O	O
:	:	O	O
2.6	2.6	O	O
-	-	O	O
32.4	32.4	O	O
%	%	O	O
)	)	O	O
.	.	O	O

Eleven	eleven	O	O
patients	patients	O	O
progressed	progressed	O	O
during	during	O	O
therapy	therapy	O	O
.	.	O	O

Grade	grade	O	O
3	3	O	O
-	-	O	O
4	4	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
included	included	O	O
myelosuppression	myelosuppression	O	S_disease
,	,	O	O
fatigue	fatigue	O	S_disease
,	,	O	O
somnolence/depressed	somnolence/depressed	O	B_disease
mood	mood	O	I_disease
,	,	O	O
neuropathy	neuropathy	O	S_disease
and	and	O	O
dyspnea	dyspnea	O	O
.	.	O	O

Of	of	O	O
concern	concern	O	O
was	was	O	O
the	the	O	O
occurrence	occurrence	O	O
of	of	O	O
four	four	O	O
thromboembolic	thromboembolic	O	B_disease
events	events	O	I_disease
.	.	O	O

Our	our	O	O
results	results	O	O
failed	failed	O	O
to	to	O	O
demonstrate	demonstrate	O	O
an	an	O	O
important	important	O	O
response	response	O	O
rate	rate	O	O
to	to	O	O
single	single	O	O
agent	agent	O	O
thalidomide	thalidomide	S_chemical	O
in	in	O	O
indolent	indolent	O	O
lymphomas	lymphomas	O	O
and	and	O	O
contrast	contrast	O	O
with	with	O	O
the	the	O	O
higher	higher	O	O
activity	activity	O	O
level	level	O	O
reported	reported	O	O
with	with	O	O
the	the	O	O
second	second	O	O
generation	generation	O	O
immunomodulatory	immunomodulatory	O	O
agent	agent	O	O
,	,	O	O
lenalidomide	lenalidomide	S_chemical	O
.	.	O	O

